Does BCBS Rhode Island cover Zepbound?

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation (>= 30 kg/m2 for obesity, or >= 27 kg/m2 for overweight)
• Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
• Age documentation (>= 18 years)

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended

Policy note: Available as both subcutaneous injection solution vial and Kwikpen formulations. Efficacy assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation (>= 30 kg/m2 for obesity, or >= 27 kg/m2 for overweight)
• Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
• Age documentation (>= 18 years)

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended

Policy note: Available as both subcutaneous injection solution vial and Kwikpen formulations. Efficacy assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate to severe OSA confirmed by polysomnography (PSG) or home sleep apnea testing (HSAT)
• AHI, REI, or RDI result documenting moderate to severe OSA (AHI >= 15 events/hour)
• Baseline BMI >= 30 kg/m2 (obesity)
• Age >= 18 years

Not covered when

• Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria)
• Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Evidence of daytime hypercapnia
• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended

Policy note: FDA indication is for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two Phase 3 trials) enrolled participants with mean AHI ~50 events/hour and mean BMI ~39 kg/m2. Trial 1 enrolled patients not on PAP therapy; Trial 2 enrolled patients on PAP therapy. The document notes AHI from PSG is the preferred diagnostic index; REI (HSAT-based) is acceptable surrogate but may underestimate severity; RDI may identify arousal-based disease. PAP therapy trial is NOT required as a prerequisite per the clinical rationale. OSA AHI minimum set to 15 events/hour based on the definition of moderate OSA (the FDA indication requires 'moderate to severe'). AASM recommended hypopnea scoring: >= 3% oxygen desaturation and/or arousal.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 18 and older
• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of moderate to severe OSA confirmed by polysomnography (PSG) or home sleep apnea testing (HSAT)
• AHI, REI, or RDI result documenting moderate to severe OSA (AHI >= 15 events/hour)
• Baseline BMI >= 30 kg/m2 (obesity)
• Age >= 18 years

Not covered when

• Craniofacial abnormalities affecting respiration (per SURMOUNT-OSA exclusion criteria)
• Predominantly central or mixed sleep apnea (>= 50% central or mixed apneas/hypopneas)
• Cheyne-Stokes respiration
• Obesity hypoventilation syndrome
• Evidence of daytime hypercapnia
• Coadministration with other tirzepatide-containing products not recommended
• Coadministration with any GLP-1 receptor agonist not recommended

Policy note: FDA indication is for moderate to severe OSA in adults with obesity. The SURMOUNT-OSA program (two Phase 3 trials) enrolled participants with mean AHI ~50 events/hour and mean BMI ~39 kg/m2. Trial 1 enrolled patients not on PAP therapy; Trial 2 enrolled patients on PAP therapy. The document notes AHI from PSG is the preferred diagnostic index; REI (HSAT-based) is acceptable surrogate but may underestimate severity; RDI may identify arousal-based disease. PAP therapy trial is NOT required as a prerequisite per the clinical rationale. OSA AHI minimum set to 15 events/hour based on the definition of moderate OSA (the FDA indication requires 'moderate to severe'). AASM recommended hypopnea scoring: >= 3% oxygen desaturation and/or arousal.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf